Эволюционное развитие технологий лучевой терапии местно-распространенного рака шейки матки

Эволюционное развитие технологий лучевой терапии местно-распространенного рака шейки матки

Автор: Солодкий В.А., Титова В.А., Паньшин Г.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры, лекции

Статья в выпуске: 4 т.22, 2022 года.

Бесплатный доступ

За последние два десятилетия парадигмы лучевой терапии полностью перешли от двумерного подхода (2D), основанного исключительно на анатомических костныхориентирах, к трехмерному (3D) индивидуальному дозиметрическому планированию под визуальным контролем с учетом различия в размере, положении опухоли и органов риска (ОР) для более точного подведения очаговых доз к клиническим мишеням с одновременным максимальным щажением ОР. В данной статье кратко представлены достижения в области дистанционной лучевой терапии (ДЛТ) и автоматизированной брахитерапии (БТ) для лечения местнораспространенного рака шейки матки. Внимание акцентировано на исторической эволюции от технологий 2D-лучевой терапии к 3D-конформной лучевой терапии (3D CRT) с последующим переходом к лучевой терапии с модулированной интенсивностью (IMRT), которая в настоящее время становится стандартом планирования и реализации ДЛТ. Обсуждены достижения БТ, в частности, эволюция от манчестерской системы БТ в условиях низкой мощности дозы излучения до внедряемой в настоящее время адаптивной БТ под трехмерным визуальным контролем (3D-IGABT). В этом контексте уделено внимание недавно проведенным крупным когортным исследованиям, которые показали значительное улучшение местного контроля (МК) и снижение токсичности, связанной с применением технологии 3D-IGABT. Кратко отмечены и другие технологические достижения в лучевой терапии инвазивного местнораспространенного рака шейки матки.

Еще

Местно-распространенный рак шейки матки, дистанционная лучевая терапия, брахитерапия, эволюция технологий лучевой терапии

Короткий адрес: https://sciup.org/149142263

IDR: 149142263

Список литературы Эволюционное развитие технологий лучевой терапии местно-распространенного рака шейки матки

  • Arbyn M., Weiderpass E., Bruni L., et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020. V. 8. No. 2. P. e191-e203. DOI: 10.1016/S2214-109X(19)30482-6.
  • Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. V. 68. No. 6. P. 394-424. DOI: 10.3322/caac.21492.
  • Brenner D.R., Weir H.K., Demers A.A., et al. Canadian Cancer Statistics Advisory Committee. Projected estimates of cancer in Canada in 2020. CMAJ. 2020. V. 192. No. 9. P. E199–E205. DOI: 10.1503/cmaj.191292.
  • Benard V.B., Watson M., Saraiya M., et al. Cervical cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer. 2017. V. 123. (Suppl. 24). P. 5119-5137.
  • Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2017. Available online: https://www.canada.ca/en/public-health/services/chronicdiseases/cancer/canadian-cancer-statistics.html (accessed on February 02, 2021).
  • Han K., Milosevic M., Fyles A., et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013. V. 87. No. 1. P. 111-119. DOI: 10.1016/j.ijrobp.2013.05.033.
  • Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. I Clin Oncol. 2008. V. 26. No. 35. P. 5802-5812. DOI: 10.1200/JCO.2008.16.4368.
  • Chino J., Annunziata C.M., Beriwal S., et al. The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes Gynecol Oncol. 2020. V. 159. No. 3. P. 607-610. DOI: 10.1016/j.ygyno.2020.09.015.
  • Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999. V. 340. No. 15. P. 1137-1143. DOI: 10.1056/NEJM199904153401501.
  • Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999. V. 340. No. 15. P. 1154-1161. DOI: 10.1056/NEJM199904153401503.
  • Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999. V. 17. No. 5. P. 1339-1348. DOI: 10.1200/JCO.1999.17.5.1339.
  • Peters. W.A. 3rd., Liu P.Y., Barrett R.J. 2nd., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000. V. 18. No. 8. P. 1606-1613. DOI: 10.1200/JCO.2000.18.8.1606.
  • Rose P.G., Bundy B.N., Watkins E.B. at al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999. V. 340. No. 15. P. 1144-1153. DOI: 10.1056/NEJM199904153401502.
  • Lee J., Lin J.B., Chang C.L., et al. Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes. Gynecol Oncol. 2018. V. 148. No. 2. P. 291-298. DOI: 10.1016/j.ygyno.2017.12.003.
  • Ping Q., Zeng J., Sun P., et al. Efficacy of preoperative brachytherapy for controlling vaginal bleeding in early-stage cervical cancer: a retrospective study. Transl Cancer Res. 2021. V. 10. No. 7. P. 3259-3267. DOI: 10.21037/tcr-21-467.
  • Yang H., Feng C., Cai B.N., et al. Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical. Dis Esophagus. 2017. V. 30. No. 2. P. 1-8. DOI: 10.1111/dote.12497.
  • Arul Ponni T.R., Avinash H.U., Nirmala S., et al. Optimal technique of radiotherapy for carcinoma cervix in developing countries: Dosimetric and logistic comparison. J Cancer Res Ther. 2018. V. 14. No. 6. P. 1207-1213. DOI: 10.4103/jcrt.JCRT_454_17.
  • Green J.A., Kirwan J.M., Tierney J. F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet. 2001. V. 358. No. 9284. P. 781-786. DOI:10.1016/S0140-6736(01)05965-7.
  • Husstedt W., Oberheuser F. [Results of irradiation in recurrent collum carcinoma]. Fortschr Med. 1977. V. 95. No. 6. P. 355-357.
  • Kim R.Y., McGinnis L.S., Spencer S.A., et al. Conventional four-field pelvic radiotherapy technique without computed tomography-treatment planning in cancer of the cervix: Potential geographic miss and its impact on pelvic control. Int J Radiat Oncol Biol Phys. 1995. V. 31. No. 1. P. 109-112. DOI: 10.1016/0360-3016(94)00337-К.
  • Bonin S.R., Lanciano R.M., Corn B.W., et al. Bony landmarks are not an adequate substitute for lymphangiography in defining pelvic lymph node location for the treatment of cervical cancer with radiotherapy. Int J Radiat Oncol Biol Phys. 1996. V. 34. No. 1. P. 167-172. DOI: 10.1016/0360-3016(95)02055-1.
  • Ambrose J., Hounsfield G. Computerized transverse axial tomography. Br J Radiol. 1973. V. 46. No. 542. P. 148-149. DOI: 10.1259/0007-1285-46-552-1023.
  • Gerstner N., Wachter S., Knocke T.H. et al. The benefit of Beam’s eye view based 3D treatment planning for cervical cancer. Radiother. Oncol. 1999. V. 51. P. 71-78. DOI: 10.1016/s0167-8140(99)00038-9.
  • Olofsen-van Acht M.J., Quint S., Seven M., et al. Three-Dimensional Treatment Planning for Postoperative Radiotherapy in Patients with Node-Positive Cervical Cancer Comparison between a Conventional and a Conformal Technique. Strahlenther Onkol. 1999. V. 175. No. 9. P. 462–469. DOI: 10.1007/s000660050037.
  • Vargo J.A., Kim H., Choi S., et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: Analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys. 2014. V. 90. No. 5. P. 1091-1098. DOI: 10.1016/j.ijrobp.2014.08.013.
  • Portelance L., Chao K.S., Grigsby P.W., et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001. V. 51. No. 1. P. 261-266. DOI: 10.1016/s0360-3016(01)01664-9.
  • Rose B.S., Aydogan B., Liang Y., et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011. V. 79. No. 3. P. 800-807. DOI: 10.1016/j.ijrobp.2009.11.010.
  • Simpson D.R., Song W.Y., Moiseenko V., et al. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin. Int J Radiat Oncol Biol Phys. 2012. V. 83. No. 1. P. e81-e86. DOI: 10.1016/j.ijrobp.2011.12.012.
  • Huang. J., Gu F., Ji T., et al. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: A single-center prospective randomized controlled trial. Radiat. Oncol. 2020. V. 15. No. 1. Article ID 180. DOI: 10.1186/s13014-020-01606-3.
  • Gandhi A.K., Sharma D.N., Rath G.K., et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: A prospective randomized study. Int J Radiat Oncol Biol Phys. 2013. V. 87. No. 3. P. 542-548. DOI: 10.1016/j.ijrobp.2013.06.2059.
  • Gandhi. A.K., Sharma D.N., Rath G.K., et al. Long Term Clinical Outcome and Late Toxicity of Intensity Modulated Versus Conventional Pelvic Radiation Therapy for Locally Advanced Cervix Carcinoma. J Clin Diagn Res. 2019. V. 13. Issue 03. P. XC09–XC13. DOI:10.7860/JCDR/2019/40260.12741.
  • Lin. Y., Chen K., Lu Z., et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: A meta-analysis. Radiat Oncol. 2018. V. 13. Article ID 177. DOI: 10.1186/s13014-018-1126-7.
  • Klopp A.H., Moughan J., Portelance L., et al. Hematologic toxicity in RTOG 0418: A phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013. V. 86. No. 1. P. 83-90. DOI: 10.1016/j.ijrobp.2013.01.017.
  • Chan P., Dinniwell R., Haider M.A., et al. Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: A cinematic-MRI point-of-interest study. Int J Radiat Oncol Biol Phys. 2008. V. 70. No. 5. P. 1507-1515. DOI: 10.1016/j.ijrobp.2007.08.055.
  • Jadon R., Pembroke C.A., Hanna C.L., et al. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clin Oncol (R. Coll. Radiol). 2014. V. 26. No. 4. P. 185-196. DOI: 10.1016/j.clon.2013.11.031.
  • Bondar L., Hoogeman M., Mens J.W., et al. Toward an individualized target motion management for IMRT of cervical cancer based on model-predicted cervix-uterus shape and position. Radiother Oncol. 2011. V. 99. No. 2. P.240-245. DOI: 10.1016/j.radonc.2011.03.013.
  • Liang Y., Bydder M., Yashar C.M., et al. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys. 2013. V. 85. No. 2. P. 406-414. DOI: 10.1016/j.ijrobp.2012.04.044.
  • Shelley C.E., Barraclough L.H., Nelder C.L., et al. Adaptive Radiotherapy in the Management of Cervical Cancer: Review of Strategies and Clinical Implementation. Clin Oncol. (R Coll Radiol). 2021. V. 33. No. 9. P. 579-590. DOI: 10.1016/j.clon.2021.06.007.
  • Han K., Milosevic M., Fyles A., et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013. V. 87. No. 1. P. 111-119. DOI: 10.1016/j.ijrobp.2013.05.033.
  • Tod M.C., Meredith W.J. A dosage system for use in the treatment of cancer of the uterine cervix. Br J Radiol. 1938. V. 11. No. 132. P. 809-824. DOI: 10.1259/0007-1285-11-132-809.
  • Tod M., Meredith W. Treatment of cancer of the cervix uteri-A revised “Manchester method”. Br J Radiol. 1953. V. 26. No. 305. P. 252-257. DOI: 10.1259/0007-1285-26-305-252.
  • Haie-Meder C., Pötter, R., Van Limbergen E., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005. V. 74. No. 3. P. 235-245. DOI: 10.1016/j.radonc.2004.12.015.
  • Pötter R., Haie-Meder C., Van Limbergen E., et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006. V. 78. No. 1. P. 67-77. DOI: 10.1016/j.radonc.2005.11.014.
  • Hellebust T.P., Kirisits C., Berger D., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol. 2010. V. 96. No. 2. P. 153-160. DOI: 10.1016/j.radonc.2010.06.004.
  • Viswanathan A.N., Erickson B., Gaffney D.K., et al. Comparison and consensus guidelines for delineation of clinical target volume for CT-and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014. V. 90. No. 2. P. 320-328. DOI: 10.1016/j.ijrobp.2014.06.005.
  • Image Guided Intensity Modulated External Beam Radiochemotherapy and MRI Based Adaptive Brachytherapy in Locally Advanced Cervical Cancer (EMBRACE-II) Study Protocol v.1.0. Rumpold. 2016. Available online: https://www.embracestudy. dk/UserUpload/PublicDocuments/EMBRACE%20II%20Protocol.pdf (accessed on October 19, 2022). DOI :10.1136/ijgc-2021-003056.
  • Dimopoulos J.C., Kirisits C., Petric P., et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Clinical feasibility and preliminary results. Int J Radiat Oncol Biol Phys. 2006. V. 66. V. 83-90. DOI: 10.1016/j.ijrobp.2006.04.041.
  • Tanderup K., Nielsen S.K., Nyvang G.-B., et al. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer. Radiother Oncol. 2010. V. 94. No. 2. P. 173-180. DOI: 10.1016/j.radonc.2010.01.001.
  • Fokdal L., Sturdza A., Mazeron R., et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol. 2016. V. 120. No. 3. P. 434-440. DOI: 10.1016/j.radonc.2016.03.020.
  • Serban M., Kirisits C., de Leeuw A., et al. Ring versus ovoids and intracavitary versus intracavitary-interstitial applicators in cervical cancer brachytherapy: Results from the EMBRACE I study. Int J Radiat Oncol Biol Phys. 2020. V. 106. P. 1052-1062. DOI: 10.1016/j.ijrobp.2019.12.019.
  • Charra-Brunaud C., Harter V., Delannes M., et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study. Radiother Oncol. 2012. V. 103. No. 3. P. 305-313. DOI: 10.1016/j.radonc.2012.04.007.
  • Sturdza A., Potter R., Fokdal L.U., et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016. V. 120. No. 3. P. 42-443. DOI: 10.1016/j.radonc.2016.03.011.
  • Haas J.A., Witten M.R., Clancey O., et al. CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy. Front Oncol. 2012. V. 2. Article ID 25. DOI: 10.3389/fonc.2012.00025.
  • Albuquerque K., Tumati V., Lea J., et al. A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2020. V. 106. No. 3. P 464-471. DOI:10 1016/j.ijrobr. 2019.10042.
  • Hashimoto S., Shibamoto Y., Iwata H., et al. Whole-pelvic radiotherapy with spot-scanning proton beams for uterine cervical cancer: a planning study. J Radiat Res. 2016. V. 57. No. 5. P. 524-532. DOI: 10.1093/jrr/rrw052.
  • Song W.Y., Huh S.N., Liang Y., et al. Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer. J Appl Clin Med Phys. 2010. V. 11. Issue 4. P. 83-92. DOI: 10.1120/jacmp.v11i4.3255.
  • Dinges E., Felderman N., McGuire S., et al. Bone marrow sparing in intensity modulated proton therapy for cervical cancer: efficacy and robustness under range and setup uncertainties. Radiother Oncol. 2015. V. 115. No. 3. P. 373-378. DOI: 10.1016/j.radonc.2015.05.005.
  • Marnitz S., Wlodarczyk W., Neumann O., et al. Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation – an intraindividual comparison. Radiat. Oncol. 2015. V. 10. Article ID 91. DOI: 10.1186/s13014-015-0402-z.
  • Lin L.L., Kirk M., Scholey J., et al. Initial report of pencil beam scanning proton therapy for posthysterectomy patients with gynecologic cancer. Int J Radiat Oncol Biol Phys. 2016. V. 95. No. 1. P. 181-189. DOI: 10.1016/j.ijrobp.2015.07.2205.
  • Vyfhuis M.A.L., Fellows Z., McGovern N., et al. Preserving endocrine function in premenopausal women undergoing whole pelvis radiation for cervical cancer. Int J Part Ther. 2019. V. 6. No. 1. P. 10-17. DOI: 10.14338/ijpt-d-19-00061.1.
Еще
Статья научная
SciUp 2024 © 2024 ©